Tuning the Brain

Deep-brain stimulation is allowing neurosurgeons to adjust the neural activity in specific brain regions to treat thousands of patients with myriad neurological disorders.

Written byAndres Lozano
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

DEEP-BRAIN STIMULATION (DBS): Electrodes implanted into targeted brain regions deliver electrical stimulation to either excite or inhibit activity in a neural circuit of interest. DBS patients are also fitted with battery-powered implanted pulse generators, typically placed subcutaneously below the clavicle and connected to the electrodes via insulated wires. These pulse generators can deliver electrical stimulation from 20 to 200 times per second. © THOM GRAVESThe world’s first neurosurgeries took place about 7,000 years ago in South America with the boring of holes into hapless patients’ skulls, a process known as trephination. Practitioners of the day believed the source of neurologic and psychiatric disease to be evil spirits inhabiting the brain, and the way to treat such disorders, they reasoned, was to make holes in the skull and let the evil spirits escape. The procedure was surprisingly common, with as many as 1 percent of skulls at some archaeological sites having these holes.

Today, neurosurgeons are still drilling into the brains of patients suffering from neurologic and psychiatric disorders, but rather than letting evil spirits escape, doctors are putting things in—inserting electrical probes to tame rogue neurons or to stimulate brain regions that are underperforming. This procedure, known as deep-brain stimulation (DBS), was first tried for the treatment of pain in the 1960s, and has since been attempted in patients with numerous other neurologic disorders. DBS is currently approved in the U.S. or Europe for the treatment of essential tremor, Parkinson’s disease, dystonia (a motor disorder that causes extreme twisting and repetitive motions), epilepsy, and obsessive-compulsive disorder (OCD). The therapy is currently in clinical trials for depression, Alzheimer’s disease, addiction, and more.

Each of these disorders is a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies